School of Pharmacy - News

Funding was granted from the Horizon Europe Programme to the NEMESIS project investigating the role of environmental chemicals as disrupters of normal human metabolism.

The University of Eastern Finland coordinates two funded Flagships, GeneCellNano and UNITE, and is a partner in the ACCC Flagship.

Bisphosphonates are commonly used to treat, for example, ostoporosis. One approach to mitigate their side effects is to utilize controlled delivery and release systems.

The results of the PhD study improve the understanding of molecular mechanisms underlying inflammasome activation in age-related macular degeneration and UV radiation-induced corneal inflammation.

Professor Jarkko Rautio was granted funding for an Academy Project called “Boosting delivery of LAT1-targeted boron carriers for improved boron neutron capture therapy”.

Finland has a strong public health care system; nevertheless, personal wealth is associated with the costs of hospital care and medication in people with Alzheimer’s disease.

The Finnish Research Impact Foundation’s new funding scheme gives professors the opportunity to spend one year working on their research with an industry partner, in an industry environment.

Researchers at the School of Pharmacy developed a new method for the accurate determination of the water content of water-soluble compounds. This plays a significant role in, e.g., drug dosage.

The U.S. Food and Drug Administration, FDA, has granted research funding to too ocular drug projects.

For the first time ever, researchers used the transporter protein OATP1C1, which is found in the brain, to enhance drug delivery into the brain, and especially into glial cells.